All values are anonymous and never stored with your name.
Sex
About this assessment
The GLP-1 Check readiness assessment is a free, anonymous 13-question screening tool built for Indian adults considering semaglutide (Ozempic, Wegovy, Noveltreat, Obeda, Semaglyn, and other DCGI-approved generics). It maps your self-reported inputs against Indian clinical eligibility criteria and produces a score from 0 to 100 classified as Green (likely eligible), Amber (further assessment recommended), or Red (contraindications present or threshold not met). It takes under 5 minutes and requires no login or personal information.
Basic metrics
Height, weight, waist circumference, age, sex, and ethnicity. Calculates BMI using Indian cut-offs (≥23 overweight, ≥25 obesity) rather than Western thresholds.
Comorbidities
Type 2 diabetes, hypertension, PCOS, cardiovascular disease, fatty liver, sleep apnea, dyslipidaemia. Each lowers the BMI eligibility threshold per ESI India guidelines.
Contraindications
Medullary thyroid carcinoma, MEN2 syndrome, prior pancreatitis, pregnancy, and other absolute contraindications. Any hard flag produces a Red result regardless of score.
Lifestyle & history
Prior GLP-1 exposure, recent hospitalisation, substance use, prior weight-loss approaches, diet quality, and activity level. Optional: blood markers (HbA1c, fasting glucose, lipids, BP).
South Asians develop visceral fat, insulin resistance, and cardiometabolic disease at lower BMI values than European populations. ICMR-INDIAB, WHO Asia-Pacific, and ESI India guidelines all set the obesity threshold at BMI 25 (not 30) and the overweight threshold at 23 (not 25). Using Western thresholds on Indian patients misses approximately 1 in 3 people who are metabolically obese by Indian criteria.
This assessment uses Indian thresholds throughout. If you have been told you are “not obese” at BMI 28 under Western criteria, your Indian clinical profile may still qualify you for GLP-1 therapy. Read the ICMR-INDIAB-23 evidence →
Green — likely eligible
Your profile aligns with published eligibility criteria. A physician must still review your full history and order baseline labs before prescribing.
Amber — consult a doctor
Your inputs show some positive and some borderline indicators. A clinical consultation, possibly with blood tests, will clarify whether GLP-1 therapy fits your specific situation.
Red — alternatives likely more appropriate
One or more self-reported factors suggest GLP-1 therapy may not be appropriate at this time. A Red result does not mean no options — your doctor can discuss alternative weight management strategies.
Every scoring weight is mapped to a specific published source. Full references are in the Evidence Library. Key sources include:
Important
This tool is an informational screening instrument, not a medical diagnosis, prescription, or substitute for clinical consultation. Semaglutide is a Schedule H prescription drug in India and can only be legally obtained from a registered medical practitioner after a full clinical evaluation. GLP-1 Check does not sell, dispense, or prescribe medication. Always consult a qualified physician — preferably an endocrinologist or internal medicine specialist — before starting any treatment. See all 40 FAQs →
